ARMC5 mutations in a large French-Canadian family with cortisol-secreting β-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia

Isabelle Bourdeau1,2, Sylvie Oble1, Fabien Magne1, Isabelle Lévesque1, Katia Y Cáceres-Gorriri1, Serge Nolet3, Philip Awadalla4, Johanne Tremblay1, Pavel Hamet2, Maria Candida Barisson Villares Fragoso5 and André Lacroix1

1Division of Endocrinology, Department of Medicine and 2Division of Medical Genetics, Department of Medicine, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Quebec, Canada, 3Department of Pathology, CHUM, Montréal, Quebec, Canada, 4Department of Pediatrics, Centre de Recherche CHU Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada and 5Unidade de Suprarrenal, Disciplina de Endocrinologia e Metabologia, Laboratório de Hormônios e Genética Molecular LIM42, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Correspondence should be addressed to I Bourdeau
Email isabelle.bourdeau@umontreal.ca

Abstract

Background: Bilateral macronodular adrenal hyperplasia (BMAH) is a rare cause of Cushing’s syndrome (CS) and its familial clustering has been described previously. Recent studies identified that ARMC5 mutations occur frequently in BMAH, but the relation between ARMC5 mutation and the expression of aberrant G-protein-coupled receptor has not been examined in detail yet.

Methods: We studied a large French-Canadian family with BMAH and sub-clinical or overt CS. Screening was performed using the 1-mg dexamethasone suppression test (DST) in 28 family members. Screening for aberrant regulation of cortisol by various hormone receptors were examined in vivo in nine individuals. Sequencing of the coding regions of ARMC5 gene was carried out.

Results: Morning ambulating cortisol post 1 mg DST were > 50 nmol/l in 5/8 members in generation II (57–68 years old), 9/22 in generation III (26–46 years old). Adrenal size was enlarged at different degrees. All affected patients increased cortisol following upright posture, insulin-induced hypoglycemia and/or isoproterenol infusion. β-blockers led to the reduction of cortisol secretion in all patients with the exception of two who had adrenalectomies because of β-blockers intolerance. We identified a heterozygous germline variant in the ARMC5 gene c.327_328insC, (p.Ala110Argfs*9) in nine individuals with clinical or subclinical CS, in four out of six individuals with abnormal suppression to dexamethasone at initial investigation and one out of six individuals with current normal clinical screening tests.

Conclusions: Systematic screening of members of the same family with hereditary BMAH allows the diagnosis of unsuspected subclinical CS associated with early BMAH. The relation between the causative ARMC5 mutation and the reproducible pattern of aberrant β-adrenergic and V1-vasopressin receptors identified in this family remains to be elucidated.
Introduction

Primary adrenal etiologies of Cushing's syndrome (CS) are responsible for 15–25% of cases of endogenous overt hypercortisolism, which are mainly due to adrenal adenomas and carcinomas (1). Rarely, CS is secondary to primary bilateral adrenal hyperplasias (<2%), and this includes primary bilateral macronodular adrenal hyperplasia (BMAH) (2). Most BMAH cases were initially reported as sporadic, but more than ten kindreds of familial BMAH were reported in recent years, and in all cases their presentation suggested an autosomal dominant mode of transmission (3, 4, 5, 6, 7, 8, 9, 10). The true prevalence of hereditary BMAH may have been underestimated because familial screening was not performed systematically (2).

In the last two decades, the regulation of steroidogenesis in BMAH was elucidated in part following the identification of aberrant expression and function of several G-protein-coupled receptors (GPCR) in BMAH tissues (11). The aberrant stimulation of steroidogenesis can be under the control of ectopic receptors such as those for glucose-dependent insulinotropic peptide, catecholamines (β-adrenergic receptor), vasopressin (V2–V3-vasopressin receptor), serotonin (5-HT2 receptor), glucagon, and probably angiotensin II receptor (AT1R). It can also result from increased expression or altered activity of eutopic receptors such as those for vasopressin (V1-vasopressin receptor), luteinizing hormone (LH)/human chorionic gonadotropin, serotonin (5-HT4 receptor), and leptin receptor (11, 12). In addition, adrenocorticotropic hormone (ACTH) can be produced in clusters of steroi dogenic cells in BMAH tissues and regulate steroidogenesis in a paracrine manner (13). ACTH was not regulated by corticotropin-releasing hormone (CRH) or glucocorticoid receptor, but was stimulated by aberrant receptor activation. Cortisol production in BMAH is therefore modified both by aberrant GPCR and autocrine ACTH, which amplifies the aberrant receptor effects (13).

The genetic basis of hereditary BMAH appears to be heterogeneous (12, 14, 15). A limited number of cases of BMAH were described in association with the multiple endocrine neoplasia type 1 syndrome (14, 15) and the hereditary leiomyomatosis and renal cancer syndrome (14, 16). Although BMAH may be associated with McCune–Albright syndrome (GNAS1), only a few cases of sporadic BMAH with somatic GNAS1 mutations were reported (16, 17). BMAH was also found in patients with familial colon polyps and adenomatous polyposis coli (APC) gene mutation (14, 16).

Recently, using single-nucleotide polymorphism (SNP) arrays, linkage analysis and whole genome sequencing, germline and somatic ARMC5 gene mutations were identified in 18/33 (55%) patients with apparently sporadic BMAH and CS (18). Similarly, pathogenic ARMC5 mutations were found in a second cohort of 34 apparently sporadic cases of BMAH with CS with a prevalence of 20.6% (19) and very recently ARMC5-damaging mutations were identified in 24/98 (26%) index cases of BMAH (20). Furthermore, we and others identified causal germline ARMC5 mutations in six families with BMAH (21, 22, 23).

The relation between ARMC5 mutation and the expression of aberrant GPCR in BMAH has not yet been examined in detail. Preliminary studies have found that ARMC5 mutation carriers may present aberrant response to upright posture, vasopressin and metoclopramide tests; in contrast, none of the patients with food-dependent CS carried ARMC5 mutations (18, 20, 23).

We describe a French-Canadian BMAH kindred with β-adrenergic and V1-vasopressin regulation of cortisol in which nine members of the family are affected, including seven with sub-clinical and two with clinical CS. A heterozygous germline ARMC5 mutation was identified in the index case that segregates with the disease in the family.

Subjects and methods

Clinical details and endocrine investigations of probands

Proband II-1 ▶ We previously reported on this 56-year-old man with BMAH and CS with aberrant β-adrenergic and V1-vasopressin response (24) (Table 1 for endocrine investigation and radiological findings). In this patient, cortisol secretion increased during the change from supine to upright posture, the arginine–vasopressin test (10 IU i.m.), a treadmill stress test, an insulin-induced hypoglycemia and isoproterenol infusion (Figs 1 and 2) (24). Cortisol secretion was not modified by mixed meal, thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), glucagon, and cisapride. Treatment with the β-adrenergic-antagonist propranolol blocked the cortisol increase when upright. Since propranolol (up to 320 mg daily) greatly reduced but not normalized 24-h urinary free cortisol (UFC) levels, a left unilateral adrenalectomy was performed and the diagnosis of BMAH was confirmed at histology. Therapy with propranolol was resumed after the surgery and UFC...
Table 1  Summary of clinical data and endocrine investigation of the nine members of the family affected by bilateral macronodular adrenal hyperplasia (BMAH).

<table>
<thead>
<tr>
<th>Patients</th>
<th>II-1</th>
<th>II-3</th>
<th>II-7</th>
<th>II-8</th>
<th>II-9</th>
<th>III-2</th>
<th>III-4</th>
<th>III-5</th>
<th>III-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>56</td>
<td>65</td>
<td>59</td>
<td>59</td>
<td>56</td>
<td>46</td>
<td>44</td>
<td>42</td>
<td>44</td>
</tr>
<tr>
<td>Sex (F, M)</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
</tr>
<tr>
<td>Clinical presentation</td>
<td>Phlebitis, weight gain</td>
<td>Familial screening</td>
<td>Adrenal incidentalomas</td>
<td>Familial screening</td>
<td>Familial screening</td>
<td>Familial screening</td>
<td>Familial screening</td>
<td>Familial screening</td>
<td>Familial screening</td>
</tr>
<tr>
<td>Plasmas cortisol after 1 mg dexamethasone (nmol/l)</td>
<td>499 (2 mg)</td>
<td>333</td>
<td>489</td>
<td>98</td>
<td>580</td>
<td>650</td>
<td>251</td>
<td>119</td>
<td>119</td>
</tr>
<tr>
<td>Unirary free cortisol ([n]: 90–330 nmol/day)</td>
<td>1963–2953</td>
<td>123</td>
<td>187–252</td>
<td>152</td>
<td>144</td>
<td>126</td>
<td>772</td>
<td>144</td>
<td>250</td>
</tr>
<tr>
<td>Basal ACTH ([n]: 2–11 pmol/l)</td>
<td>0.86</td>
<td>1.6</td>
<td>1.3</td>
<td>4.3</td>
<td>&lt;2.2</td>
<td>1.1</td>
<td>&lt;0.5</td>
<td>&lt;0.5</td>
<td>5.2</td>
</tr>
<tr>
<td>4 mg-DEX IV (nmol/l)</td>
<td>709</td>
<td>323</td>
<td>801</td>
<td>59</td>
<td>138</td>
<td>615</td>
<td>130</td>
<td>44</td>
<td>45–574</td>
</tr>
<tr>
<td>Posture test</td>
<td>469–828 (177%)</td>
<td>325–940 (289%)</td>
<td>461–710 (154%)</td>
<td>164–262 (160%)</td>
<td>47–89 (189%)</td>
<td>601–867 (144%)</td>
<td>129–216 (167%)</td>
<td>139–366 (263%)</td>
<td>ND</td>
</tr>
<tr>
<td>Insulin-induced hypoglycemia test</td>
<td>709–1396 (197%)</td>
<td>ND</td>
<td>462–703 (152%)</td>
<td>194–417 (215%)</td>
<td>39–232 (595%)</td>
<td>776–1151 (148%)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Treadmill stress test</td>
<td>519–811 (156%)</td>
<td>609–664 (109%)</td>
<td>514–752 (146%)</td>
<td>236–376 (159%)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Isoproterenol</td>
<td>703–1446 (206%)</td>
<td>ND</td>
<td>416–937 (225%)</td>
<td>170–478 (281%)</td>
<td>73–239 (159%)</td>
<td>438–944 (216%)</td>
<td>130–292 (225%)</td>
<td>141–332 (259%)</td>
<td>105–140 (133%)</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>491–1057 (215%)</td>
<td>184–654 (355%)</td>
<td>715–998 (140%)</td>
<td>216–474 (220%)</td>
<td>458–895 (269%)</td>
<td>141–332 (195%)</td>
<td>82–162 (198%)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Desmopressin</td>
<td>574–588 (102%)</td>
<td>163–117 (72%)</td>
<td>357–382 (107%)</td>
<td>220–181 (82%)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Right adrenal gland</td>
<td>Nodular</td>
<td>One nodule</td>
<td>Multiple nodules</td>
<td>Nodule 9 mm</td>
<td>Two nodules of 8 mm</td>
<td>Nodule 8 mm</td>
<td>Nodular and one nodule 8.5 mm</td>
<td>Nodule 10 mm (HU24) and nodule 6 mm (HU14)</td>
<td></td>
</tr>
<tr>
<td>Left adrenal gland</td>
<td>Nodular</td>
<td>Nodular</td>
<td>Multiple nodules</td>
<td>Nodule 7 mm</td>
<td>One nodule 13×8 mm and one nodule 23×20 mm (HU &lt;10)</td>
<td>Nodule 25×16 mm (HU26)</td>
<td>Nodular 23×25 mm</td>
<td>Three nodules between 10 and 12 mm</td>
<td>Nodule 10 mm (HU15) and nodule 20 mm (HU26)</td>
</tr>
</tbody>
</table>

ND, not done; F, female; M, male.

*a cortisol < 50 nmol/l.

*b cortisol < 76 nmol/l the morning following 4 mg-IV dexamethasone perfusion.
became normalized with decreasing doses of propranolol
to 20–40 mg daily. Seventeen months after the surgery,
UFC increased up to 451 nmol/day (normal: 90–330)
when propranolol was stopped inadvertently. Fifteen
years following the initial adrenalectomy, abdominal
computed tomography showed no change in the size of
the right adrenal gland (Fig. 3). His UFC remain well
controlled with atenolol 50 mg daily, while control of
blood pressure required the addition of irbesartan–
hydrochlorothiazide 300/12.5 mg, and nifedipine XL
20 mg daily. A posture test was repeated under atenolol
and showed an increase of plasma cortisol from 430 to
642 nmol/l (149%), which is slightly less than the initial
increase of 177%. The most recent morning plasma ACTH
value was low at <0.5 pmol/l (n: 2–11), while his UFC
remained normal at 190 nmol/day (90–330).

**Proband II-7** A 59-year-old brother of the first patient
was referred 10 years later after his brother for an
incidentally found bilateral adrenal enlargement (Table 1
and Fig. 2). He had been diagnosed with high blood
pressure, requiring four medications and dyslipidemia
since age 40. The patient reported asthenia, a weight gain
of 36 kg during the last 4 years, and proximal muscle
weakness during the last 2 years. Physical examination
revealed high blood pressure (158/80 mmHg), facial
plethora, and truncal obesity. Despite normal UFC levels,
ACTH levels were low at 1.1 pmol/l with no increase
following CRH stimulation test, and cortisol was not
suppressed by overnight dexamethasone test (Table 1).
Similarly to his brother, cortisol secretion was stimulated
by upright posture (154%), a treadmill stress test (146%),
insulin-induced hypoglycemia (152%), and isoproterenol
infusion (225%) in addition to arginine–vasopressin
(140%) (Table 1 and Fig. 1). Treatment with propranolol
120 mg twice daily did not completely block the increase
in cortisol during upright posture (plasma cortisol from
174 to 334 nmol/l (192%)). The patient was treated with
nadolol 20 mg twice daily for 10 months and the patient
reported a weight loss of 7 kg, reduction in central obesity,
and normalization of his hypertension. The posture test
was repeated 10 months later under nadolol (normal UFC)
and plasma cortisol increased from 314 to 486 nmol/l (154.8%).
Vasopressin stimulation increased plasma corti-
sol from 312 to 624 nmol/l (200%), while the computed
tomography (CT) scan showed no change in the adrenal
glands size. Unfortunately, the patient died from a massive
stroke 1 year later.

**Clinical screening for prevalence of familial BMAH**

First-degree adult family members of probands II-1 and
II-7 were offered clinical screening for BMAH. All
patients signed an informed consent under the research
protocol approved by the Institutional Review Board of
the Centre Hospitalier de l’Université de Montréal
(CHUM).

Basal investigations included a complete medical
evaluation, physical examination and a 1 mg overnight
dexamethasone suppression test (DST) using a normal
plasma cortisol cut-off <50 nmol/l. When 1 mg DST
showed abnormal suppression, a 24-h urine collection for measurement of UFC, 4 mg-IV DST (normal: plasma cortisol $<76$ nmol/l at 0900 h on the morning following dexamethasone) and a CT scan of adrenal glands with no contrast were performed.

The diagnostic criteria used for primary CS were: increased UFC (>330 nmol/day), morning plasma cortisol $>50$ nmol/l following overnight 1 mg DST, $>76$ nmol/l the morning following 4 mg-IV DST, and plasma ACTH levels $<2$ pmol/l (in 2–11). The diagnostic criteria for sub-clinical CS included normal UFC with sub-normal suppression of plasma cortisol levels following 4 mg-IV DST ($>76$ nmol/l) and low basal plasma ACTH levels ($<2$ pmol/l) (25).

**In vivo screening for the presence of aberrant hormone receptors**

In all patients with confirmed abnormal suppression to 4 mg-IV DST, the *in vivo* screening for the presence of aberrant hormone receptors was performed as described previously (25, 26). In addition, in patients from generation II with normal suppression to 1 and/or 4 mg-IV DST, posture and vasopressin stimulations were performed as additional tests. Subjects with sub-clinical CS received dexamethasone 1 mg orally every 6 h for 24–48 h before and during all the investigations to ensure that ACTH levels remained suppressed.

Plasma levels of cortisol, ACTH, aldosterone, and renin were measured at 30–60 min intervals for 2–3 h during tests that transiently modulate the levels of ligands for potential aberrant receptors (11). All tests were done at fasting with the patient in supine posture for at least 60 min prior to the tests. On day 1, an upright posture test lasting 2 h was followed by a standard mixed meal, and by 1–24 ACTH, 250 µg i.v. (Cortrosyn, Organon Canada, Scarborough, ON, Canada). On a second day, the administration of 100 µg GnRH i.v. (Factrel, Wyeth-Ayerst, Montréal, QC, Canada) was followed by 200 µg TRH i.v. (Relefact, Hoechst-Roussel, Montréal, QC,
Confirmation of the V₁-vasopressin-responsive cortisol secretion

When a significant response to vasopressin was found, further tests included a 2.5 μg s.c. of V₂-vasopressin receptor agonist desmopressin (dDAVP, Ferring, Inc.).

Assays

Plasma cortisol, FSH, LH, thyroid-stimulating hormone, and prolactin were measured by immunofluorometric assay (Bayer Immuno I System, Tarrytown, NY, USA) and ACTH by immunoradiometric assay (Allegro, Nichols Diagnostics, San Juan Capistrano, CA, USA). Plasma aldosterone and renin activity were measured by RIA Kits (DSL, Webster, TX, USA).

Patients and adrenocortical samples

DNA was extracted from peripheral lymphocytes from 18 members of the family, eight from generation II and ten from generation III, by standard methods. BMAH tissue specimens were obtained at surgery from patients II-1 and III-4 and were immediately frozen in liquid nitrogen and stored at −80 °C. Tumor DNA was extracted from frozen tissues as described previously (27).

Analysis for mutations of ARMC5 gene

All six exons of the coding regions were screened for the presence of ARMC5 gene mutations. We used the primers previously described (18) and we designed two new sets of primers for the amplification of exon 1. The number of cycles and the annealing temperatures used for PCR amplification are detailed in Supplemental Table 1 (see section on supplementary data given at the end of this article). The PCR products were separated on a 2% agarose gel and detected using a PhosphoImager. The amplicons were directly sequenced using Sanger sequencing in both directions (McGill University and Génome Québec, Montréal, QC, Canada).

In silico analyses and comparison with controls in CARTaGENE database

We used the in silico software Mutation Taster (28) and SNAP (29) to predict the damaging potential of the genetic alterations found in lymphocyte and tumoral DNA samples. We compared the identified genetic alterations to data from the CARTaGENE project consisting of a cohort of 96 French-Canadian subjects (30).

Results

Following the diagnosis of two siblings with β-adrenergic/V1-vasopression responsive BMAH and clinical and sub-clinical CS, we hypothesized that other family members may be affected with BMAH (Fig. 2). Table 1 summarizes the clinical and biochemical characteristics of the nine family members found to be affected with BMAH.

Family history of the probands

The mother of the probands (II-1 and II-7) died at 82 years of age and suffered from Parkinson’s disease. Their father died at 77 with high blood pressure, diabetes, central obesity, atherosclerotic cardiovascular disease, and chronic kidney failure. In addition to six living sisters, one sister died at 3 months of age from meningitis; another sister who suffered of hypertension and dyslipidemia died at 61 of cerebral metastasis from an unknown primary cancer. A paternal cousin was diagnosed at age 62 with cortisol-secreting adrenocortical carcinoma. No other tumors were known in the family.

Prospective clinical investigation of family members of generation II (II-2, II-3, II-5, II-6, II-8, and II-9)

Endocrine investigation in the six siblings identified three individuals aged 65, 59, and 56 years old (II-3, II-8, and II-9) with unsuspected sub-clinical CS secondary to BMAH in whom cortisol was stimulated by catecholamines and vasopressin both not by mixed meal, GnRH, TRH, and tegaserod/metoclopramide. The three other siblings of 67, 63, and 61 years old (II-2, II-5, and II-6) showed normal suppression following DST and no significant increase of cortisol during the upright posture and vasopressin tests. Aldosterone/renin ratios were normal in all cases.

Affected individuals in generation II (II-3, II-8, and II-9)

Patient II-3  The 65-year-old woman presented high blood pressure treated during the last 2 years with hydrochlorothiazide 25 mg and amlodipine 5 mg once daily and osteoporosis. Physical examination revealed facial plethora, sus-clavicular fat pads and a buffalo hump. Initial endocrine investigation showed abnormal 1-mg oral and 4-mg i.v. DST, but normal UFC (Table 1). Bilateral adrenal nodules were found on abdominal CT scan (Fig. 3). Cortisol secretion was stimulated by upright posture (289%) and vasopressin (355%). In light of past medical history of cardiac arrhythmias, insulin tolerance test and isoproterenol infusion were not performed. Propranolol 40 mg four times during 3 days partially decreased the cortisol response to the posture test from 289 to 165%. No significant response of cortisol to isoproterenol, LHRH or TRH tests were found. The patient is treated with nadolol 80 mg once daily and her UFC levels remained within the normal range.

Patient II-8  This 59-year-old woman had benign breast tumors, choledocholithiasis, dyslipidemia, and pulmonary bronchiectasis. She was diagnosed at age 55 with osteoporosis and is a heterozygous carrier of factor V Leiden mutation. Physical exam was normal. She had sub-normal suppression to 1 mg-DST and aberrant cortisol response to upright posture test (278%) and to vasopressin stimulation (173%) but not to desmopressin (122%). Aberrant regulation of cortisol was confirmed with the insulin tolerance test (476%) and the isoproterenol infusion (377%). Under β-blockers, cortisol response to upright posture decreased only slightly from 278 to 219%. Abdominal CT-scan showed the presence of two 1-cm lesion on each adrenal gland. She has been treated with nadolol 40 mg once daily and is stable with sub-clinical CS.

Patient II-9  Their 56-year-old sister reported hypertension of 5 years duration treated with Irbesartan 300 mg/hydrochlorothiazide 25 mg. She was also found to have osteoporosis and underwent resection of a meningioma at age 54. On physical examination, there was diffuse obesity with a BMI of 28. There was abnormal suppression of cortisol to 1 mg-IV DST (580 nmol/l) and 4 mg-IV DST (463 nmol/l), while 24-h UFC was normal. CT showed bilateral adrenal enlargement (Table 1). CRH test (1 μg/kg i.v.) increased ACTH from <2.2 to 9.5 pmol/l and cortisol from 458 to 1187 nmol/l, demonstrating an incomplete ACTH suppression. Abnormal secretion of cortisol was confirmed to the upright posture test (160%) and catecholamine-dependent increase of cortisol of 215% during the insulin tolerance test, of 159% during the treadmill stress test, and of 281% during the isoproterenol infusion. There was no cortisol response following desmopressin injection. The patient was treated with propranolol 40 mg twice daily only because she was not able to tolerate higher doses of β-blockers due to hypotension.

Non-affected individuals in generation II (II-2, II-5, and II-6)  Individual II-2 (67-year-old woman) with type 2 diabetes and hypertension, had normal suppression to DST (1 mg overnight: 39 nmol/l and 4 mg IV: 45 nmol/l). Family member II-5 is a 63-year-old woman diagnosed...
with hypertension, impaired glucose tolerance, obesity, hypothyroidism and symptomatic cholelithiasis. She had normal DST and UFC levels and a non-significant response in cortisol to the upright posture (128%). Individual II-6 was a 61-year-old woman with high blood pressure, benign breast nodules and osteoporosis who had had hysterectomy at age 34. She was under carbamazepine for trigeminal neuralgia and her physical exam showed no sign of CS, and UFC was normal. DST was slightly sub-normal (62 nmol/l) under carbamazepine; following its discontinuation for 1 week, a 4 mg-IV DST was normal at 78 nmol/l. She showed no response to posture and vasopressin stimulations.

**Prospective clinical investigation of family members of generation III**

Among the 30 family members of generation III, 22 individuals (13 females and nine males) aged 25–46 consented for at least the 1 mg-DST. Thirteen individuals (nine females and four males) showed normal suppression. Among the nine individuals showing abnormal cortisol suppression to the 1 mg-DST, four subjects underwent further tests that confirmed sub-clinical CS in three subjects (two males of 46 (III-2) and 44 (III-10) years old, and one female 42-year-old (III-5)), and CS in one 44-year-old female (III-4). Among the affected individuals from generation III, there are one son (III-2) and two daughters (III-4 and III-5) of proband II-1 with sub-clinical (n: 2) and clinical (n: 1) CS and a son (III-10) of patient II-3 with a diagnosis of sub-clinical CS (Fig. 1). All these individuals had abnormal cortisol suppression to 4 mg-IV DST and were examined in vivo for the presence of aberrant cortisol response to catecholamines and vasopressin. Their aldosterone/renin ratios were within the normal limits.

**Individual III-4**  This 44-year-old gained 12 kg during the last 3 years. At screening, there was no suppression of cortisol to the 1 mg-DST (650 nmol/l) nor later to 4 mg-IV DST (615 nmol/l). UFC was increased at 772 nmol/day with undetectable plasma ACTH levels (<0.5 pmol/l). Similar to her father (proband II-1), her cortisol levels increased following posture test (144%), insulin tolerance test (148%), and isoproterenol infusion (216%) and after vasopressin (195%). Her adrenal CT-scan revealed multinodular adrenal glands (Table 1 and Fig. 3). She was treated with nadolol 40 mg once daily and her UFC decreased to 284 nmol/day. The response of cortisol to upright posture test remained significant (149%) although nadolol was increased up to 60 mg daily. Nadolol was replaced by pindolol 5 mg twice daily because of bradycardia; One year later UFC increased to 1099 nmol/day with signs of CS. Upright posture tests were repeated under pindolol and clonidine 0.3 mg (cortisol increased from 658 to 1002 nmol/l, 152%) and the selective α1 receptor antagonist prazosin (cortisol increased from 590 to 1302 nmol/l (221%)). A bilateral adrenalectomy was performed.

**Individual III-2**  This 46-year-old man had subnormal suppression to 1 mg DST (85 nmol/l). He had no complaints and his physical examination was normal. Sub-clinical CS mediated by catecholamines/vasopressin was confirmed by upright posture test (189%), the insulin tolerance test (595%), the isoproterenol infusion (327%), and vasopressin stimulation (269%). Unsuspected adrenal masses were seen at CT-scan (left nodule 15×26 mm; right nodule of 8 mm) (Fig. 3). He is currently treated with nadolol 20 mg once daily.

**Individual III-5**  This 42-year-old woman experienced 5 kg weight loss during the last year and has no high blood pressure or diabetes. Her physical exam was normal except for diffuse obesity with no CS stigmata. The investigation revealed the presence of sub-clinical CS with abnormal cortisol secretion to catecholamines-mediated stimuli (Table 1). Her CT-scan demonstrated bilateral adrenal Nodules. She was treated with nadolol 20 mg once daily as well.

**Individual III-10**  This 44-year-old man had no significant past medical history. His endocrine investigation revealed an unsuspected sub-clinical CS as well with catecholamine and vasopressin responses (Table 1). His CT-scan revealed bilateral adrenal lesions. A bone density revealed unknown osteoporosis with a T-score of −2.6 in L1–L4 areas. He is also treated with nadolol.

**Mutational analysis of ARMC5 gene**

A heterozygous germline ARMC5 non-sense mutation c.327_328insC (p.Ala110Argfs*9) was identified in lymphocyte DNA of the index case II-1 (Fig. 2). The *in silico* modeling of protein function of this ARMC5 mutation was predicted as damaging using Mutation Taster (28) and non-neutral using SNAP (29) predicting that it is disease-causing. This genetic alteration was not found in 96 French-Canadian controls. Two additional somatic ARMC5 variants were found in the adrenal tissue of patient II-1; i) the heterozygote silent mutation c.288C>G; p.A96A and ii) a somatic non-sense mutation
C.2029G>T (p.E677X). This last pathogenic somatic mutation supports the hypothesis of the tumor suppressor role of ARMC5. The daughter (III-4) of II-1 who was affected by cortisol-secreting BMAH and CS at age 44 carries the germline heterozygous c.327_328C (p.Ala110Argfs*9) ARMC5 mutation as well, but in addition carries a germline heterozygous p.A705V ARMC5 genetic alteration reported as a gene polymorphism (rs11150624) (Table 2). This variant was found in 50% of our cohort of 96 French-Canadian individuals (30).

The germline pathogenic ARMC5 non-sense mutation c.327_328insC (p.Ala110Argfs*9) was found in nine individuals with clinical or subclinical CS, in 2/5 individuals with abnormal suppression to dexamethasone at initial investigation and 1/6 individuals (this individual was 40 years old) (from generation III) with normal clinical screening tests.

**Discussion**

To our knowledge, we describe the largest family with hereditary BMAH characterized extensively for the presence of aberrant hormone receptors, including nine affected members with clinical or subclinical CS. All the affected members expressed the same β-adrenergic/V1-vasopressin-responsive cortisol secretion phenotype that was extensively characterized previously in vivo and in vitro in the propositus (24). The first BMAH family with β-adrenergic/vasopressin-responsive cortisol secretion was described in 2002 by Miyamura et al. (5) and included an affected mother and son, but no other members of the family were investigated. Here, we identified sub-clinical CS in three females and one male and clinical CS in a male from generation II. Moreover, unexpected sub-clinical CS was diagnosed prospectively in two males and one female and clinical CS in one female from generation III. Among all the patients investigated in this study, 5/8 (63%) living individuals from generation II and 9/22 (41%) individuals tested from generation III showed at least abnormal suppression to the 1 mg DST. Although diagnosis of BMAH was confirmed in all 5/5 subjects in generation II, only 4/9 individuals from generation III with an abnormal 1 mg DST have undergone complete confirmatory tests for the presence of BMAH. As described previously in other families, we observed an autosomal dominant pattern of transmission of the disease (21).

Our prospective familial clinical screening of BMAH following diagnosis of the index cases was conducted several years before the identification of the gene implicated in familial BMAH. The diagnosis of hereditary
BMAH will now be facilitated as an ARMC5 mutation has been found in an index case. Patients with apparently sporadic BMAH should be offered genetic counseling for germline ARMC5 gene analysis and because BMAH has an autosomal mode of transmission, if the propositus is found to carry mutations in ARMC5, genetic testing should be offered to all first-degree relatives. However, some families with BMAH do not carry ARMC5 mutations and are likely carriers of another genetic mutation not yet identified. Thus, clinical screening with 1 mg-DST and imaging as utilized in this study will be necessary for BMAH families with no identified germline mutation causing disease. Our prospective clinical screening strategy allowed us to identify six subjects with unsuspected sub-clinical CS and one female with unknown CS and BMAH. As observed by Alencar et al. (21) and Elbelt et al. (22), the 1 mg-overnight DST is the most sensitive screening method and far superior to UFC for the identification of subjects with unsuspected secreting BMAH. Considering the long-term deleterious effects of hypercortisolism, the early diagnosis of cortisol-secreting BMAH is of importance. Although the surgical treatment of sub-clinical CS remains controversial, the identification of aberrant-regulation of cortisol by various receptors including β-adrenergic and V1-AVPR allowed us to treat medically several patients with sub-clinical or clinical CS with β-blockers. For example, in proband II-1, adjuvant therapy with β-blockers after a unilateral adrenalectomy enabled the long-term control of hypercortisolism, and avoided bilateral adrenalectomy with the risk of acute adrenal insufficiency (24) Although the long-term effects of β-blockers in subjects with aberrant combined β-AR and V1-AVPR with sub-clinical CS remain to be evaluated, in the 18 years’ follow-up of proband II-1 stabilization of adrenal gland size and secretion with long-term medical treatment were confirmed. However, the coexistence of more than one aberrant GPCR, including AVPR1 in this family, may limit the success of monotherapy with β-blockers, as shown by the incomplete abolition of cortisol response to upright posture and the requirement of bilateral adrenalectomy in patient III-4. Based on in vitro data demonstrating the frequent expression of α2A adrenergic receptor (ADRA2A), we examined whether cortisol was regulated by clonidine or prazosin, but we found no such response in individual III-4 (31).

Other BMAH kindreds were described with adrenal aberrant receptors. Imölhl et al. described a 44-year-old male and his mother affected by catecholamine-dependent BMAH (7). Lee et al. (8) described two sisters (46 and 58 years old) with BMAH, meningiomas, and ectopic expression of vasopressin V1b and V2 receptors. A French family with BMAH was found to have aberrant S-HT3 and vasopressin adrenal receptors in three siblings (two females of 54 and 56 years old, and one 57-year-old male) and their 81-year-old father (9). Very recently, in an Australian kindred carrying an ARMC5 mutation, vasopressin-responsive BMAH was present in seven members of the family (23); two other Australian BMAH families with partial endocrine investigation suggested vasopressin responsiveness in a father and a son in one family, and in three siblings in the second family (10). In contrast to the family in this study, these authors found no correlations between DST or vasopressin and the diagnosis of BMAH ascertained by adrenal imaging. Our study of a large Brazilian family with BMAH demonstrated that the aberrant responses to vasopressin or metoclopramide were not consistently present in all affected individuals (15).

As found recently in other BMAH kindreds (21, 22, 23), we identified a damaging germline non-sense c.327_328insC (p.Ala110Argfs*9) mutation of ARMC5 in all the clinically affected members of our kindred. As expected, some mutation carriers are still too young to express clinical disease and a longer follow-up will be necessary to assess the penetrance of the genetic alteration. Very recently, Ebelt et al. (22) described a German family with a heterozygous c.323_324insC ARMC5 mutation which is the same mutation that we report here, although according to the recommendations by the Human Genome Variation Society, it should be preferentially named c.327_328insC. In contrast to studies on sporadic cases (18, 19), we had access to only two BMAH tissues and found a second additional somatic ARMC5 mutation in the BMAH tissue as reported by Gaggiardi et al. (23). In addition to the causative germline mutation, we found a second germline heterozygous A705V ARMC5 alteration in the daughter who presented a very early onset of severe BMAH (even though a second somatic mutation was not found); although this latest genetic alteration reported as a gene polymorphism (rs11150624) does not affect the main ARMC5 transcript but instead the ARMC5 isoform b precursor, it is intriguing that an isolated non-damaging alteration of a potential ARMC5 transcript accelerates the clinical evolution of the disease. It can also be speculated that other somatic events can accelerate the phenotype such as those identified recently in the highly conserved methyltransferase domain of DOT1L, in the histone deacetylase gene HDAC9, which were not examined in this patient’s tissues (32). The paternal cousin of the propositus developed an adenocortical carcinoma but was not a carrier of the ARMC5 mutation identified.
We conclude that this ACC was coincidental or at least not due to this ARMC5 gene alteration.

As ARMC5 is a widely expressed gene in a large number of human tissues and functions as a tumor-suppressor gene, it is relevant to investigate whether other tumors develop in patients or families carrying inactivating ARMC5 mutations (33). Intracranial meningiomas were present in a Korean family with BMAH (8) and in 43% of the Brazilian family members with germline ARMC5 mutations and BMAH (21), while they are diagnosed in only 0.9% of the general population after the fourth decade of life. Very recently, in the German family carrying the ARMC5 c.323_324insC (p.Ala110Argfs*9) mutation a damaging somatic ARMC5 mutation was shown in a concomitant meningioma but not in a pancreatic tumor found in an affected subject (22). In this family, there was only one case of resected meningioma patient II-9 (no tissue available for analysis) and no history of other neoplasias.

This is a first study in which a familial BMAH family is extensively characterized for the presence of aberrant hormone receptors associated with an ARMC5 mutation. The adrenocortical expression of high affinity binding sites compatible with β1- or β2-adrenergic receptors efficiently coupled to steroidogenesis in the BMAH tissues in these patients, but not in normal adrenal cortex indicated the ectopic nature of this receptor (5, 24). The apparent genetic transmission of the same receptor phenotype in all affected family members supported the hypothesis of a primary role of aberrant receptors in the pathophysiology of BMAH; however, the causal role of ARMC5 mutations in this and other BMAH families, suggests that the aberrant GPCRs are secondary events, although the mechanisms leading to their altered expression remain to be elucidated. Further studies will be necessary to clarify whether there is any relation between ARMC5 mutations and aberrant GPCR or autocrine production of ACTH in BMAH tissues.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-15-0642.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This study was supported by a salary grant Fonds de la Recherche du Québec-Santé (FRQS; I Bourdeau) and the Canadian Institutes of Health Research (I Bourdeau, A Lacroix, J Tremblay, and P Hamet).

References
Clinical Study

I Bourdeau and others

ARMCS mutation in familial BMAH


